On May 6, the FDA announced Elsa 4.0, a major upgrade to the agency's internal AI tool that is now available to all staff, and HALO — Harmonized AI and Lifecycle Operations for Data — a new platform that consolidates more than 40 separate application and submission systems across FDA centers. Elsa and HALO are being integrated so reviewers can query agency data directly inside chat without uploading documents into each session. Commissioner Marty Makary said the rollout positions FDA as a leader in AI-augmented regulation.
FDA reviewers spend significant time wrestling with fragmented systems and manually parsing submissions that can run thousands of pages. An integrated AI layer over a unified data platform changes the bottleneck — from finding the right document to interpreting what it says. It is also one of the most ambitious internal AI deployments in the US federal government, closer in scope to a private-sector platform rebuild than to a typical agency pilot.
This builds on the FDA's earlier announcement of real-time AI in clinical trials and follows the broader push to use AI to shrink agency timelines. It lands in the same week that Google, Microsoft, xAI, OpenAI, and Anthropic agreed to give the Center for AI Standards and Innovation pre-release access to frontier models. Government AI is consolidating fast — both as a user and as an evaluator of the technology.
Takeaway for learners: public-sector AI is often dismissed as slow, but the FDA's stack — internal LLM plus consolidated data backbone — is exactly the shape of architecture that private enterprises spend years trying to ship. If you're early in your career and want to see how AI actually changes a real organization, read the FDA's own posts on Elsa and HALO. The patterns there generalize to almost any large institution.